The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event? | Zendy

Naranie Shanmuganathan | Zendy; Susan Branford | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event?

Author(s) -

Naranie Shanmuganathan,

Susan Branford

Publication year - 2019

Publication title -

current hematologic malignancy reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.299

H-Index - 35

eISSN - 1558-822X

pISSN - 1558-8211

DOI - 10.1007/s11899-019-00549-1

Subject(s) - myeloid leukemia , breakpoint cluster region , hematology , medicine , disease , oncology , bioinformatics , immunology , cancer research , biology , receptor

Identification of the BCR-ABL1 fusion oncogene in patients diagnosed with chronic myeloid leukemia (CML) led to the development of targeted therapy responsible for the dramatic survival benefits observed in the past two decades. However, despite these revolutionary findings, there remains marked disparity in patient outcomes. Why do some patients present de novo while others evolve to the more aggressive stages of CML? Why can select patients successfully discontinue therapy as part of a treatment-free remission attempt whereas others fail to meet specific molecular milestones?

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research